Can India help the UK become a tech superpower?
Britain is looking for its place on the global stage in the post-Brexit, post-pandemic world. The U.K. government wants the country to be a tech superpower — but it needs to attract talent and investment. India may be able to help.
Tesla’s shares are up over 70% this year. One market pro is bullish — but another isn’t convinced
Shares of the electric vehicle giant have risen a lot this year, after falling 65% in 2022. Two investors face off on what’s next for the company.
Goldman Sachs names 5 buy-rated stocks — giving one more than 70% upside
Three of those are on Goldman’s conviction list. It revisited its stock ratings in light of recent volatility, sticking to some of them and upgrading others.
CNBC Daily Open: State of the economy: Slowing, but strong
Markets were mostly unchanged Monday. Investors are waiting for bank earnings and price reports.
S&P 500 closes little changed Tuesday as traders await March inflation report: Live updates
Two key economic data points weigh on the minds of investors this week: the latest consumer price index and the producer price index readings.
Bank of Korea holds rates; Asia markets rise as bitcoin hits $30,000
The Bank of Korea held rates at 3.50% for a second consecutive time as the nation grapples with an inflation rate of 4.2%.
A frozen IPO market signals two positive things for stocks, CNBC’s Jim Cramer says
“The incumbents are winning, and that means their earnings could be better than anyone thinks,” CNBC’s Jim Cramer said.
‘Everyone should want to own’ this discounted chip stock, says ‘Fast Money’ trader Tim Seymour
The VanEck Semiconductor ETF (SMH) is up 26% in 2023.
Deutsche Bank sees more than a 30% rally for this specialty biotech stock
Deutsche Bank upgraded Catalent on Monday to buy from hold as the company’s partnership with Moderna could help it grow market share.
Moderna says it hopes to offer new vaccines for cancer, heart disease, and other conditions by 2030
Moderna’s chief medical officer said advancements in mRNA technology since the outset of the Covid pandemic have ushered in a golden age for new vaccines.
